Request Demo

Last update 25 Oct 2025

Octreotide Acetate

Last update 25 Oct 2025

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Synthetic peptide

Synonyms

Octreotide acetate (USP), Octreotide Acetate Microspheres, 奥曲肽

+ [28]

Target

SSTR

Action

agonists

Mechanism

SSTR agonists(Somatostatin receptor agonists)

Therapeutic Areas

NeoplasmsNervous System DiseasesDigestive System Disorders+ [3]

Active Indication

GigantismNeuroendocrine neoplasm of gastrointestinal tractMalignant Carcinoid Syndrome+ [4]

Inactive Indication

Castration-Resistant Prostatic CancerCongenital HyperinsulinismDrug-induced diarrhea+ [8]

Originator Organization

Novartis Pharma AG

Active Organization

Novartis Pharmaceuticals Corp.Novartis Pharma Schweiz AG

Novartis Pharma KK

+ [5]

Inactive Organization

Novartis AG

Biodexa Pharmaceuticals Plc

License Organization

Shenzhen Kangzhe Pharmaceutical Co., Ltd.

Sandoz (China) Pharmaceutical Co., Ltd.Aspen Pharmacare Holdings Ltd.

+ [7]

Drug Highest PhaseApproved

First Approval Date

United States (21 Oct 1988),

AcromegalyCarcinoid TumorVipoma

RegulationOrphan Drug (United States), Orphan Drug (European Union)

Structure/Sequence

Molecular FormulaC51H70N10O12S2

InChIKeyXQEJFZYLWPSJOV-XJQYZYIXSA-N

CAS Registry79517-01-4

Sequence Code 19721

169

Clinical Trials associated with Octreotide Acetate

NCT06881888

/ Not yet recruitingPhase 1IIT

Intranasal Delivery of Octreotide for Treatment of Diabetic Macular Edema

Treatment of diabetic retinopathy (DR) and diabetic macula edema has included panretinal photocoagulation and intra ocular injections of anti-vascular endothelial growth factors (anti-VEGF) agents and steroids. Anti-VEGF therapy is currently the first-line treatment for proliferative diabetic retinopathies; however, this approach is ineffective in more than 30% of patients with diabetic retinal complications. Available evidence shows that subcutaneous (under the skin) injection of octreotide, a somatostatin analog, has potential therapeutic benefits in proliferative diabetic retinopathy (PDR) and diabetic macula edema (DME). This study thus seeks to determine the efficacy and safety of intranasal DDM-octreotide in the treatment of diabetic macula edema in individuals that are considered to be refractory to the current therapeutic options.

Start Date31 Aug 2026

Sponsor / Collaborator

The University of Alabama at Birmingham

NCT06558422

/ Not yet recruitingPhase 1IIT

Human Models of Selective Insulin Resistance: Pancreatic Clamp

This is a single-center, prospective, randomized, controlled (crossover) clinical study designed to investigate the impact of lowering insulin levels on hepatic glucose production (HGP) vs de novo lipogenesis (DNL) in people with insulin resistance. The investigators will recruit participants with a history of overweight/obesity and evidence of insulin resistance (i.e., fasting hyperinsulinemia plus prediabetes and/or impaired fasting glucose and/or Homeostasis Model Assessment of Insulin Resistance [HOMA-IR] score >=2.73), and with evidence of metabolic dysfunction-associated steatotic liver disease (MASLD). Participants will undergo two pancreatic clamp procedures -- one in which serum insulin levels are maintained near hyperinsulinemic baseline (Maintenance Hyperinsulinemia or "MH" Protocol) and the other in which serum insulin levels are lowered by 50% (Reduction toward Euinsulinemia or "RE" Protocol). In both clamps the investigators will use stable-isotope tracers to monitor hepatic glucose and triglyceride metabolism. The primary outcome will be the impact of steady-state clamp insulinemia on HGP vs DNL.

Start Date01 Jan 2026

Sponsor / Collaborator

Columbia University

[+2]

NCT06974344

/ Not yet recruitingPhase 4IIT

Randomized Controlled Trial Protocol Comparing Splenic Artery Ligation Versus Octreotide for Portal Flow Modulation (SCALOP) in Living Donor Liver Transplantation

The goal of this clinical trial is to compare two treatments for regulating blood flow in small liver grafts during living donor liver transplantation (LDLT). The main questions it aims to answer are:
* Is octreotide (a medication) as effective or better than splenic artery ligation (surgery) in reducing complications after transplantation?
* Which treatment better controls blood flow while causing fewer side effects?
Researchers will compare octreotide (given through an IV) to splenic artery ligation (performed during surgery) to see which approach works best for patients receiving small liver grafts.
Participants will:
* Be randomly assigned to receive either octreotide or splenic artery ligation during their transplant surgery
* Have their liver blood flow monitored closely during and after surgery
Be followed for 90 days and 1 year to track complications, hospital stay, recovery, and survival.
This study may help doctors choose safer, more effective treatments for patients needing small liver grafts.

Start Date01 Jun 2025

Sponsor / Collaborator

King Faisal Specialist Hospital & Research Centre

100 Clinical Results associated with Octreotide Acetate

100 Translational Medicine associated with Octreotide Acetate

100 Patents (Medical) associated with Octreotide Acetate

4,042

Literatures (Medical) associated with Octreotide Acetate

01 Jul 2025·Clinical Pharmacology in Drug Development

Pharmacokinetic and Bioequivalence Evaluation of Prolonged‐Release Octreotide Acetate Microspheres in Healthy Human Subjects

Article

Author: Hu, Haixun ; Fu, Yao ; Cao, Yu ; Hao, Chenxi ; Li, Yanzhi ; Yang, Qingmin ; Wang, Chenjing ; Liu, Yanping ; Lv, Zhaoguo ; Gu, Xingli ; Sun, Yanhua ; Li, Xin

Abstract:

Somatostatin analogs such as octreotide have been used in the treatment of acromegaly in the past decades, due to their efficacy in relieving symptoms and lowering growth hormone and insulin‐like growth factor 1 levels. Herein, the pharmacokinetic (PK) profile and safety of generic (test product) octreotide acetate microspheres and brand name (reference product) octreotide acetate microspheres in healthy volunteers were compared to assess the bioequivalence. Healthy volunteers were randomized 1:1 to receive single doses of the test product and reference product, respectively. Blood samples of each patient were collected at specific time intervals over an 82‐day period. Plasma drug concentrations were tested. The PK parameters were analyzed and compared. Analysis of variance on log‐transformed primary PK parameters was applied to analyze the bioequivalence between the test and reference product. The bioequivalence margin was 80%‐125%. The PK parameters between the 2 groups were numerically similar. All 90% confidence intervals of the geometric mean ratio for the primary PK parameters fell within 80%‐125%, confirming the bioequivalence of the 2 drugs. In this study, 172 (73.9%) adverse events, including 1 (0.4%) non‐treatment‐related serious adverse event in the test group, were reported. The test product is bioequivalent to the reference product with acceptable safety. The octreotide acetate microspheres provided by 2 sponsors are alternative products.

01 Jul 2025·Research in Pharmaceutical Sciences

Octreotide and direct/indirect lung injury

Review

Author: Nematbakhsh, Mehdi ; Pezeshki, Zahra ; Choopani, Samira ; Zarei, Ghasem

Background and purpose::

Lung injury is one of the most important diseases, which is accompanied by hypoxemia, organ failure, and a high mortality rate. There are several symptoms and causes of lung injuries. In the past years, special attention has been given to investigating the pathophysiology and the treatment of this disease. Octreotide, as an anti-inflammatory, anti-secretory, tissue-repairing, and anti-fibrotic drug, has been considered and administered for the treatment of lung injury. This review article considered the pharmacological effects of octreotide on physiopathological conditions in patients or animal models that have direct or indirect lung injury.

Search strategy and findings::

Keywords including “octreotide” OR “sandostatin” AND “lung injury” OR “ARDS” OR “respiratory distress” OR “lung fibrosis” were searched in the database of PubMed, and 44 articles were found. According to the direct or indirect lung injury, the articles were classified.

Conclusion::

It appears that octreotide is a protective drug for the treatment of direct and indirect lung injuries, exhibiting anti-inflammatory, anti-hypersecretory, anti-fibrotic, and anti-neutrophil permeability effects, while also increasing endogenous antioxidants. However, there is still room for extensive research to fully clarify the effectiveness of octreotide for direct or indirect lung injury.

01 May 2025·PANCREATOLOGY

Somatostatin analogs for resectable pancreatic neuroendocrine tumors in high-risk surgical patients: Data from a single-center cohort

Article

Author: Landoni, Luca ; Cingarlini, Sara ; Corvino, Gaetano ; Gronchi, Federico ; Marchetti, Alessio ; Malleo, Giuseppe ; Casciani, Fabio ; Salvia, Roberto ; Cattelani, Alice ; Fontana, Michele ; Maistri, Giulia ; De Robertis Lombardi, Riccardo ; D'Onofrio, Mirko ; Paiella, Salvatore

OBJECTIVES:

To evaluate the use of long-acting somatostatin-analogs (SSA) for treating non-advanced, resectable pancreatic neuroendocrine tumors (PNETs) with indications to surgery, in high-risk patients who were not candidates for surgery.

METHODS:

Patients diagnosed with histology-proven, non-advanced G1/low-G2 68Ga-TC/PET-positive PNETs >20 mm who did not undergo surgery due to comorbidities/old age/high-risk surgical profile, which were treated with SSA at a single, high-volume institution were included. The efficacy of SSA was evaluated using the analysis of tumor growth rate (TGR). "Negative TGR_Tx-TpreSSA" was defined as the first time point after the initiation of SSA when a negative TGR_Tx-TpreSSA was observed.

RESULTS:

Between 2014 and 2024, 20 patients were treated with long-acting SSA. The median age was 76 (IQR 72-80), and the median ASA score was 3 (IQR 3-3). Fifteen patients (75 %) received Lanreotide, and five (25 %) octreotide acetate (Sandostatin® LAR). The median overall survival was 68.5 months (IQR 60-99). In four patients (20 %), SSA were interrupted when the tumor had shrunk below 2 cm. In one of them, SSA reintroduction was necessary due to disease progression (after 14 months). In two patients (10 %), the treatment was interrupted due to side effects. In one of these, the disease progressed until death at 87 years old. At the last follow-up, sixteen patients were alive, 3 had died (1 death of disease), and 13 were receiving SSA. T2 PNETs presented a significantly faster response to SSA therapy compared to T3 (Median time to "Negative TGR_Tx-TpreSSA": 6 [95 % CI 5, na] vs 52 [95 % CI 19, na] months, respectively; p = 0.0092) CONCLUSION: In patients at high surgical risk, with localized, resectable, G1 or low-G2, 68Ga-TC/PET-positive PNETs >20 mm, SSA can obtain disease control with a manageable safety profile.

118

News (Medical) associated with Octreotide Acetate

26 Sep 2025

·firstwordpharma.com

Crinetics’ daily oral acromegaly pill earns FDA nod for first-line use

Crinetics Pharmaceuticals on Thursday said the FDA greenlit its nonpeptide somatostatin receptor type 2 (SST2) agonist Palsonify (paltusotine), making a first-line once-daily oral option available for adults with acromegaly who are refractory to or unsuitable for surgery. The product, which could offer patients freedom from frequent injections of current therapies, is expected to hit the shelves early next month — with a $290,000 yearly treatment price.Palsonify’s clearance “marks a new era for those living with acromegaly,” said Scott Struthers, chief executive of Crinetics, adding that the “approval is the first to come from our deep pipeline of first-in-class, small molecule drugs.” The FDA decision was supported by two Phase III pivotal trials, PATHFNDR-1 and PATHFNDR-2, which enrolled previously treated and treatment-naïve adults with acromegaly, respectively. In both studies, A significantly higher proportion of participants receiving Palsonify maintained IGF-1 levels ≤1 times the upper limit of normal compared with those on placebo, alongside significant reductions in acromegaly-associated symptoms. Moreover, 91% of PATHFNDR-1 and 97% of PATHFNDR-2 participants enrolled in open-label extension studies, highlighting durable IGF-1 control and sustained symptom improvements.Analysts’ predictions materialiseAnalysts at HC Wainwright last month said they were pretty confident of an approval for Palsonify, with a label enabling broad use across treatment-naïve patients, those switching from injectables, and those who discontinued therapy. They anticipate “treatment-naïve patients to drive the first wave of adoption post launch, with the other two groups to pick up momentum over time.”The optimism was echoed by Citizens JMP analysts, assigning a 90% probability of approval.. Considering patients with acromegaly visit endocrinologists infrequently, they expect a modest early launch, modelling revenues of $2 million this year and $45 million in 2026.While injectables, including somatostatin analogues and growth hormone receptor antagonists, make up the bulk of the acromegaly treatments, the FDA in 2020 approved Chiesi’s oral somatostatin analogue Mycapssa (octreotide) for long-term maintenance in injectable somatostatin responders. However, Palsonify is the first oral therapy okayed for front-line use in this condition.The drug remains under review in the EU, with a decision expected in the first half of next year. At the same time, Crinetics is partnering with Sanwa Kagaku Kenkyuso to develop and commercialise the therapy in Japan. Crinetics is also investigating the SST2 agonist in a Phase III study for carcinoid syndrome. With cash reserves of $1.2 billion providing a runway into 2029, the company’s pipeline also boasts ACTH antagonist atumelnant being studied in congenital adrenal hyperplasia and Cushing’s syndrome, and a non-peptide drug conjugate CRN09682 for neuroendocrine tumours among others..

Phase 3Drug ApprovalClinical ResultOligonucleotide

26 Sep 2025

·endpoints.news

Crinetics gets first FDA approval as Palsonify is cleared for rare hormonal disorder

Crinetics won FDA approval for Palsonify to treat a rare condition that occurs when the pituitary gland produces too much growth hormone. The company said Thursday that Palsonify, also known as paltusotine, is a once-daily pill for adults with acromegaly. It works by targeting the somatostatin receptor type 2, which reduces the excessive release of growth hormone. Crinetics says the drug is a more convenient option than injectable somatostatin receptor ligands, like Novartis’ Sandostatin and Ipsen’s Somatuline Depot. It’s the first small molecule SSTR2 agonist, according to Stifel analysts. “There remains a significant unmet need for safe, highly efficacious, easy-to-administer treatments that offer daily control,” Crinetics chief commercial officer Isabel Kalofonos said during an earnings call in May, according to an AlphaSense transcript. The approval is based on two Phase 3 trials: one in previously treated patients and one in medically untreated patients. Palsonify met the primary endpoint in both studies, proving that it could maintain insulin-like growth factor (IGF-1) levels — a biomarker used to assess acromegaly — in patients who switched from monthly injectable treatments and lower IGF-1 levels in untreated patients. Acromegaly can cause a range of symptoms, including headache, joint aches, fatigue, bone and cartilage overgrowth, and abnormal growth of the hands and feet. Left uncontrolled, it can increase the risk of death. Analysts view the drug as an underrated asset for Crinetics, with Leerink Partners analyst Joseph Schwartz expecting a “respectable launch” that will bolster future launches. “Although the acromegaly indication is relatively small, it serves as a strategic starting point to leverage their experience and relationships within the endocrinology community,” he told investors this week. Analysts on Thursday said that Palsonify’s price at $290,000 a year is above expectations, with some having predicted it would be around $100,000. A note from TD Cowen states its price point could lead to “sales accumulating quicker” to meet forecasts. Crinetics is planning to advance a Phase 3 trial assessing the drug in patients with carcinoid syndrome. Editor’s note: This article was updated to note Palsonify’s price.

Phase 3Drug ApprovalClinical Result

28 Aug 2025

·www.prnewswire.com

Camurus announces approval of Oczyesa® for the treatment of acromegaly in the UK

LUND, Sweden, Aug. 28, 2025 /PRNewswire/ -- Camurus (NASDAQ STO: CAMX) today announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved Oczyesa®, octreotide subcutaneous depot, marketing authorization for the maintenance treatment in adult patients with acromegaly who have responded to and tolerated treatment with somatostatin analogs.1 "Oczyesa, the first once-monthly subcutaneous octreotide treatment, has shown effective and sustained control of acromegaly and can be self-administered by patients using an autoinjector pen", says Fredrik Tiberg, President & CEO, CSO at Camurus. "Camurus plans to launch the treatment in the UK in the fourth quarter of 2025." The MHRA's marketing authorization of Oczyesa is based on the results from a comprehensive clinical program comprising seven clinical studies, including two Phase 3 studies within the ACROINNOVA program. Oczyesa is formulated using Camurus' proprietary FluidCrystal® technology. The product is designed for convenient once-monthly, subcutaneous self-administration using a pre-filled autoinjector pen with a hidden, thin needle. Oczyesa was granted marketing authorization in the EU by the European Commission on 30 June 2025. For more information Fredrik Tiberg, President & CEO Tel. +46 (0)46 286 46 92 [email protected] Fredrik Joabsson, Chief Business Development Officer Tel. +46 (0)70 776 17 37 [email protected] About acromegaly Acromegaly is a rare, progressive disease, typically caused by a tumor of the pituitary gland producing excess growth hormone and stimulating increased insulin growth factor-1 (IGF-1) levels. This results in abnormal growth of bone and tissue, enlarged hands, feet, facial features and inner organs, and symptoms such as fatigue, joint pain, headache, visual field defects, excessive sweating, and paresthesia.2 Inadequate biochemical and symptom control can have detrimental impacts on quality of life and mortality of patients with acromegaly.3,4 The prevalence of acromegaly is estimated to about 60 cases per million.5 About Oczyesa® (CAM2029) Oczyesa® (CAM2029) is a ready-to-use, long-acting subcutaneous depot of octreotide indicated for maintenance treatment in adult patients with acromegaly who have responded to and tolerated treatment with somatostatin analogs.1 The product is stored at room temperature and should not be refrigerated. The CAM2029 clinical program for acromegaly comprises seven clinical trials, including four Phase 1 studies, one Phase 2 study, and two Phase 3 studies within the ACROINNOVA clinical program. CAM2029 has demonstrated an approximate five-fold higher bioavailability compared to the currently approved, long-acting, intramuscular (IM) octreotide.6 The ACROINNOVA 1 study demonstrated that treatment with Oczyesa results in a significantly higher proportion of patients achieving normalized insulin growth-factor-1 (IGF-1) levels compared to placebo. The persistence of mean IGF-1 values and reduction of symptoms were confirmed over 52 weeks in the ACROINNOVA 2 study. Furthermore, the study showed improvements in symptoms, quality of life, and treatment satisfaction scores after 52 weeks of treatment with Oczyesa compared to standard of care (SoC) at baseline.7,8 The most common side effects included gastrointestinal disorders, nervous system disorders, hepatobiliary disorders, metabolism and nutritional disorders, and injection site reactions.1 CAM2029 is under development for two additional chronic and severe disease indications: gastroenteropancreatic neuroendocrine tumors (GEP-NET) and polycystic liver disease (PLD). About Camurus Camurus is an international, science-led biopharmaceutical company committed to developing and commercializing innovative, long-acting medicines for improving the lives of patients with severe and chronic diseases. New drug products with best-in-class potential are conceived based on the company's proprietary FluidCrystal® technology and its extensive R&D expertise. The R&D pipeline includes products for the treatment of dependence, pain, cancer, and endocrine diseases. Camurus has operations across Europe, the US, and Australia, with headquarters in Lund, Sweden. The company's shares are listed on Nasdaq Stockholm under the ticker CAMX. For more information, visit and LinkedIn. References Oczyesa® SmPC. Colao A., et al. Acromegaly. Nat Rev Dis Primers. 2019;5(1):20. Webb SM, et al. Quality of Life in Acromegaly. Neuroendocrinology. 2016;103(1):106-111. Fleseriu M., et al Acromegaly: pathogenesis, diagnosis, and management. Lancet Diabetes Endocrinol. 2022 Nov;10(11):804-826. Crisafulli S., et al. Global epidemiology of acromegaly: a systematic review and meta-analysis. Eur J Endocrinology. 2021; 185:251-63. Summary of Product Characteristics, Sandostatin LAR 20 mg: Ferone, D., et al. J Clin Endocrinol Metab. Published 8 October, 2024. Press release 15 July, 2024: This information was submitted for publication at 4.45 pm CET on 28 August 2025. CONTACT: This information was brought to you by Cision The following files are available for download: WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Clinical ResultPhase 3Drug ApprovalOligonucleotidePhase 2

100 Deals associated with Octreotide Acetate

External Link

KEGG	Wiki	ATC	Drug Bank
D06495	Octreotide Acetate	H01CB02	DBSALT000130

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Gigantism	Japan	Novartis Pharma KK	20 Jun 2014
Neuroendocrine neoplasm of gastrointestinal tract	Japan	Novartis Pharma KK	25 Nov 2011
Malignant Carcinoid Syndrome	China	Novartis Pharma Schweiz AG	15 Aug 2003
Neuroendocrine Tumors	China	Novartis Pharma Schweiz AG	15 Aug 2003
Acromegaly	United States	Novartis Pharmaceuticals Corp.	21 Oct 1988
Carcinoid Tumor	United States	Novartis Pharmaceuticals Corp.	21 Oct 1988
Vipoma	United States	Novartis Pharmaceuticals Corp.	21 Oct 1988

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hepatorenal Syndrome	Phase 3	Canada	Novartis AG	01 Oct 2005
Drug-induced diarrhea	Phase 3	United States	Novartis AG	01 Dec 1999
Metastatic colon cancer	Phase 3	United States	Novartis AG	01 Dec 1999
Metastatic Colorectal Carcinoma	Phase 3	United States	Novartis AG	01 Dec 1999
Nonproliferative diabetic retinopathy	Phase 3	United States	Novartis AG	01 Nov 1999
Proliferative retinopathy with diabetes mellitus	Phase 3	United States	Novartis AG	01 Nov 1999
Neuroendocrine Carcinoma	Phase 2	United States	Novartis AG	01 Dec 2013
Congenital Hyperinsulinism	Phase 2	France	Novartis AG	01 May 2009
Castration-Resistant Prostatic Cancer	Phase 2	United States	Novartis AG	01 Jul 2007
Obesity	Phase 2	United States	Novartis AG	01 Jan 2002

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ChiCTR2400085245 (NEWS) Manual	Phase 2	Pancreatic Fistula	39	Octreotide microspheres 30 mg	vqvecphghj(zmsadxrpio) = aeeuwzqpvn erthvhgpmb (pxmrsiosoh, 3.3 - 27.5) View more	Positive	10 Oct 2025
ESPE2024	Not Applicable	Hyperinsulinism	122	Octreotide	njvoepbmyq(pestoucwlk) = gastrointestinal symptoms (20.5%), hepatobiliary injuries (31.1%), and transient hyperglycemia (49.2%). Only one patient developed necrotizing enterocolitis. afiusvcfck (fhrsibfobe )	Positive	16 Nov 2024
MACRO Registry (ENDO2024)	Not Applicable	Acromegaly	230	Oral Octreotide Capsules (OOC)	zaywyjnpvt(sdbyohpavh) = tcltrqkknl wwmuvkaqkd (wfvqfxowrj, 0.8) View more	-	01 Jun 2024
				Monotherapy with OOC	bqjlevmkxl(mblafrndgc) = citkrgawrh tdzmiactyi (bjahtpnqsw )
UEGW2023	Not Applicable	Angiodysplasia	-	Long-acting release-octreotide (LAR-OCT)	erluvkmisn(tgsmrverep) = Adverse events were registered in 2 patients, leading to drug suspension in only 1 (dysrhythmia) qscmbalwtv (jteshjmuyz )	-	15 Oct 2023
UEGW2022	Not Applicable	-	-	Octreotide	pzrhnjipin(ckiklsokrw) = ztyvzgrnhb crfbwajdcu (vsmxpgjdin, -0.1 to 0.7) View more	-	09 Oct 2022
				OCTREOTIDE (Standard Care)	pzrhnjipin(ckiklsokrw) = bkvaxqzdtp crfbwajdcu (vsmxpgjdin, 0.8 - 1.6) View more
ESMO_GI2021	Phase 2	Second line	56	Lenvatinib + Octreotide acetate LAR	pvletumuke(jjjalyukdi) = cujjwcbbxc obpelzudin (rplrebhiuo ) View more	-	03 Jul 2021
MPOWERED (ENDO2021)	Phase 3	Acromegaly	146	Oral Octreotide Capsules (OOC)	pkyimwkbcu(ejdkljdfgl) = jogdefbtsz vloqiqwqdb (ynxxrzajtk ) View more	Positive	03 May 2021
				Injectable Somatostatin Receptor Ligands (iSRLs)	pkyimwkbcu(ejdkljdfgl) = zjpvwopmao vloqiqwqdb (ynxxrzajtk ) View more
MPOWERED (ENDO2021)	Phase 3	Acromegaly	-	Oral Octreotide Capsules (OOC)	iewdwzckhw(ejvsqqqsal) = szbkkbkqhb bqwbohemoy (opfudkzcmp ) View more	Positive	03 May 2021
				Injectable somatostatin receptor ligands (iSRLs)	irtlbwwaap(ybktqipgnk) = xzfevnzpvm pithqnpkjy (eujoedglbu ) View more
MPOWERED (ENDO2021)	Phase 3	Maintenance insulin-like growth factor I \| mean integrated growth hormone	146	Oral Octreotide Capsules (OOC)	tgsddqtipr(blujcchfji) = the OOC group did not experience injection site reactions wgqgcgmwqj (trduaaciio )	Positive	03 May 2021
				Injectable Somatostatin Receptor Ligands (iSRLs)

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis